All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on a marketing authorization application for its lead drug, the hereditary angioedema treatment Rhucin. (BioWorld International)